Space companies are making a push into drug development in orbit. And Bristol-Myers wants to be on the leading edge of it.
What’s happening:
- Redwire (NYSE: RDW) and Bristol-Myers Squibb (NYSE: BMY) have formed a new partnership for an investigation to the International Space Station to study small molecule compounds leveraging Redwire’s pharmaceutical drug development platform
Why it matters:
- Drug development in microgravity has been a growing trend, with Rocket Lab (NASDAQ: RKLB) and Varda Space preparing for their next mission together following the initial success of their first mission in which Varda Space was able to successfully crystallize the HIV drug Ritonavir while in orbit
- Redwire’s pharmaceutical drug development platform has multiple different applications for new breakthrough science, including regenerative medicine, bioengineering and even developing new compounds for agriculture
Going deeper:
- Redwire is also launching a partnership with pharmaceutical company ExesaLibero Pharma to study their novel therapeutic which is aiming to prevent excess bone removal caused by diseases such as arthritis and breast cancer
The intrigue:
- Redwire will launch their new scientific experiments with Bristol-Myers Squibb and ExesaLibero Pharma in collaboration with SpaceX’s upcoming cargo resupply mission
